The apparent hemodialyzer elimination rate constant and clearance for gentamicin and tobramycin were determined during 100 routine hemodialysis treatments in 49 patients. Three different dialyzers (CDAK 3500, CF 1211, and CF 1511), which vary in membrane composition, surface area, and thickness, were evaluated. The elimination rate constant in each patient was calculated from the slope of the log serum concentration-time curves. Two different elimination rate constants for each patient were derived, one during hemodialysis (KT) and one off hemodialysis (K). The hemodialyzer elimination rate constant (KD) for each dialyzer was calculated as the difference between these two values. The hemodialyzer clearance (Cd) was calculated by multiplying the hemodialyzer elimination rate constant by the volume of distribution of the patient. The KDs of gentamicin and tobramycin by the three dialyzers were significantly different. The gentamicin KD of the CDAK 3500 was lower than the values of the CF 1211 and CF 1511 (0.086 versus 0.123 versus 0.131 h-', respectively). The Cd of the CDAK 3500 for gentamicin was also significantly lower than that of the CF 1511. Although the Cds of tobramycin for the CF 1211 and CF 1511 were 24 and 43% greater than that for the CDAK 3500, these differences were not statistically significant. The KD and Cd of tobramycin were greater than those of gentamicin for all three dialyzers. These data demonstrate that commonly used hemodialyzers vary markedly with respect to their elimination and clearance characteristics of gentamicin and tobramycin. Clinically, these observations may be helpful in designing the correct dose of gentamicin and tobramycin to achieve maximum drug safety and efficacy in hemodialysis patients.
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Numerous studies have evaluated the pharmacokinetics of gentamicin and tobramycin in patients with end-stage renal disease (ESRD). However, few and conflicting data are available that describe the pharmacokinetics and clearance of these antibiotics during hemodialysis (HD) (4-6, 8, 9, 12) . Since these studies were conducted, several new artificial kidneys have become ava-ilable. Information on the relative clearance rates of these new dialyzers would be useful in the design of rational gentamicin (G) and tobramycin (T) dosage schedules for patients undergoing HD. The purpose of this study was to clinically characterize the pharmacokinetics and clearance of G and T during hemodialysis. maintained at 500 ml/min. Blood flow was increased to a maximum rate of 225 to 250 ml/min during the first hour of dialysis. A maximal flow rate of 250 ml/min was maintained for the duration of dialysis.
MATERIALS AND METHODS
Collection and assay of specimens. Serial blood specimens were obtained during the nondialysis (minimum of three) and dialysis period (minimum of two) to assess the pharmacokinetic parameters of G or T. Samples during the nondialysis period were drawn at 2, 24, and 44 h after drug administration. The sera were separated and frozen at -20'C until they were assayed. The concentration of G and T was determined in duplicate by radioimmunoassay (Antibodies Inc., Davis, Calif.). This method permitted the accurate measurement of G and T concentrations above 1 mg/liter. The intra-and interassay coefficients of variation were less than 10%6.
Pharmacokinetic analysis. The serum concentration-time data were fitted to a single exponential term by linear leastsquares regression analysis to determine the elimination rate constant for the nondialysis (K) and dialysis (KT) period. The half-life during these periods was calculated from the relationship tla = 0.693/K. The volume of distribution (Vd) was determined by the method of Sawchuk and Zaske (13 
RESULTS
The pharmacokinetic parameters of G and T during the nondialysis period were not significantly different ( Table 1 ). The t112, K, Vd, and Cs were similar to those in previous literature reports on ESRD patients (1, 4-6, 8, 9, 12) . The t1/2 of G and T during HD with the CDAK 3500, CF 1211, and CF 1511 was markedly decreased, whereas the CT of G and T was increased ( Table 2 ). The number of patients exposed to each artificial kidney exceeds the number of patients evaluated during the nondialysis period', since some patients were dialyzed on several artificial kidneys during their course of therapy.
The above data indicate that hemodialysis with all of the dialyzers results in substantial alterations in the half-life and clearance of G and T. Alterations in volume of distribution were not assessed, since the influence of hemodialysis on Vd is minimal (11) . The observed changes in pharmacokinetics of G and T reflect the impact of HD in the clinical environment.
The KD and Cd of G by the three dialyzers were significantly different ( Table 2 ). The CDAK 3500 KD of G was significantly lower than the KD of the CF 1211 and the CF 1511 (P < 0.05; Student's t test). The CDAK 3500 Cd of G was 17.2% lower than that of the CF 1211 (P not significant) and 43.5% lower than that of the CF 1511 (P < 0.05). The KDs of T by the three dialyzers were also significantly different ( Table 2 ). The CDAK 3500 KD of T was significantly lower than the KD of the CF 1211 (P < 0.05). Although the Cds of the CF 1211 and CF 1511 were 24 and 43% greater than that of the CDAK 3500, these differences were not statistically significant. The KD and Cd of T was greater than G for all three dialyzers. The KD was only significantly greater with the CDAK 3500 (P < 0.05). The differences in Cd were not significant. However, since dialyzer performance was not equalized (i.e., creatinine and urea clearances were not maintained the same during each HD with each dialyzer), extrapolation of these results beyond the'conditions of the study may not be valid.
DISCUSSION
The pharmacokinetics of G and T in patients with ESRD have been extensively evaluated. Multiple-dosage adjust- ment methods have been proposed for the use of these agents in patients with various degrees of renal impairment (1, 2) . The effect of HD on G and T kinetics has not been as extensively reviewed. The Cd of G has been reported to range from 24 to 47.7 ml/min, whereas the Cd of T has been reported to range from 50 to 60 ml/min (2) . This variability may be related to the evaluation and subsequent comparison of dialyzers which have different surface areas, membrane composition, and membrane thickness. In addition, utilization of different blood flow rates during HD may dramatically effect Cd. Increasing the blood flow rate from 50 to 300 ml/min has been reported to increase the Cd of G by 84 to 267% (6) .
In this study the pharmacokinetics of G and T were evaluated before and during HD with three dialyzers. These dialyzers were selected for evaluation because they are commonly used and no data are available regarding the effect of HD on the kinetics of G and T. Marked variability was observed among the three dialyzers in the t1/2 during dialysis, KD, Cd, and CT for both G and T. Each dialyzer significantly shortened the t1/2 and increased the clearance of G and T compared to predialysis values. The KDs for G and T were significantly greater with the CF 1211 and/or CF 1511 than with the CDAK 3500. Similar changes were observed in Cd, although statistical significance was not attained with T. These findings suggest that the type of dialyzer utilized must be considered when designing aminoglycoside dosage regimens for ESRD patients.
Although the methodology utilized to calculate the KD and Cd of the dialyzers provides a uniform means for comparison between these dialyzers, the actual values may be overestimates of the true parameters due to a rebound phenomenon in G and T serum concentrations after HD (7). Rebound (3) . Although Bauer did not rigorously characterize the degree or time course of the rebound, the data suggest that it occurs, i.e., a mean increase of 0.73 ± 0.20 mg/liter. Despite this report, the differences observed in this study between the off-HD and on-HD states cannot be disregarded. The degree of increase in elimination rate constant and clearance in this study is significantly greater than the reported increase in G serum concentrations post-HD. Therefore, the impact of HD will need to be considered in designing G and T dosage regimens for HD patients.
Whether supplemental dosing of G and T after dialysis will be necessary will depend on when HD is initiated relative to the time the last dose was administered, the length of the dialysis treatment, the model of dialyzer utilized, the amount of ultrafiltration, and the blood and dialysate flow rates. Knowledge of the G and T KD and Cd for the dialyzer can be utilized at the initiation of therapy to predict the removal of the aminoglycoside during the HD procedure. The data for this study can be utilized with the nondialysis period estimates of the patient's kinetic parameters to design an appropriate initial dosing schedule (10) . However, due to the marked variability in the pharmacokinetic parameters of G and T during dialysis, it is recommended that the KD and/or Cd be assessed for each patient to maximize the therapeutic response and to minimize toxicity.
